We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Antibodies – News and Features

News

Affitech to Play key Role in Major EU Embryonal Tumor Pipeline Project

Proprietary discovery platforms to be utilized to identify fully human therapeutic antibody candidates.
News

NIH Selects Regeneron for Knockout Mouse Project

Regeneron will use its VelociGene® technology to target 3,500 genes over five years, providing models of human diseases.
News

Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies

Dyax will perform funded research on certain targets of Serono to identify therapeutic antibodies.
News

Research and Markets Announces Addition of the Fourth Wave: A new Generation of Protein-Based Therapeutics

Companies are developing technologies that will remodel recombinant protein and MAb therapeutics into next-generation drugs.
News

Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement

The companies plan to use Medarex's UltiMAb Human Antibody Development System® to generate antibodies to disease targets.
News

MorphoSys Obtains PER.C6® Human Cell Line from Crucell

The license agreement allows MorphoSys to use the PER.C6® cell line for production of antibody material in MOR103 program.
News

Analyze Americans' Attitudes toward Pharmacogenomics and Personalized Medicine

In this report, Research and Markets examine how the use of pharmacogenomics will affect today's drug development strategies.
News

YM Biosciences Licenses Monoclonal Antibody to Daiichi

Daiichi will develop nimotuzumab for the Japanese market in several cancer indications.
News

Lumera Invited to Demonstrate its ProteomicProcessor™ at Cold Spring Harbor Laboratory

Three week proteomics course to highlight Lumera's technology to leading academic and pharmaceutical researchers.
News

MorphoSys Announces Expansion of Collaboration with Novartis

The original therapeutic antibody collaboration agreement provided for a three-year term with an option for Novartis to extend. The collaboration will now go through May 2011.
Advertisement